187 related articles for article (PubMed ID: 32487130)
21. A survey of patients with facial angiofibromas associated with tuberous sclerosis complex: Short-, medium- and long-term efficacy and safety of topical rapamycin.
Sigg N; Fouquet J; Morin D; Farges D; Vrignaud S; Martin L
Ann Dermatol Venereol; 2023 Dec; 150(4):270-273. PubMed ID: 37821253
[TBL] [Abstract][Full Text] [Related]
22. Topical 0.1% rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: a pilot study of four patients.
Foster RS; Bint LJ; Halbert AR
Australas J Dermatol; 2012 Feb; 53(1):52-6. PubMed ID: 22309333
[TBL] [Abstract][Full Text] [Related]
23. Clinical and Histologic Analysis of the Efficacy of Topical Rapamycin Therapy Against Hypomelanotic Macules in Tuberous Sclerosis Complex.
Wataya-Kaneda M; Tanaka M; Yang L; Yang F; Tsuruta D; Nakamura A; Matsumoto S; Hamasaki T; Tanemura A; Katayama I
JAMA Dermatol; 2015 Jul; 151(7):722-30. PubMed ID: 25692384
[TBL] [Abstract][Full Text] [Related]
24. Analysis of current data on the use of topical mTOR inhibitors in the treatment of facial angiofibromas in tuberous sclerosis complex-An update.
Balestri R; Rizzoli L; Pedrolli A; Urru SAM; Rech G; Neri I; Girardelli CR; Magnano M
J Eur Acad Dermatol Venereol; 2023 Mar; 37(3):474-487. PubMed ID: 36300771
[TBL] [Abstract][Full Text] [Related]
25. Effect of Angiofibromas on Quality of Life and Access to Care in Tuberous Sclerosis Patients and Their Caregivers.
Crall C; Valle M; Kapur K; Dies KA; Liang MG; Sahin M; Huang JT
Pediatr Dermatol; 2016 Sep; 33(5):518-25. PubMed ID: 27436143
[TBL] [Abstract][Full Text] [Related]
26. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis.
Haemel AK; O'Brian AL; Teng JM
Arch Dermatol; 2010 Jul; 146(7):715-8. PubMed ID: 20644030
[No Abstract] [Full Text] [Related]
27. A novel rapamycin cream formulation improves facial angiofibromas associated with tuberous sclerosis complex: a double-blind randomized placebo-controlled trial.
Aitken P; Stanescu I; Boddington L; Mahon C; Fogarasi A; Liao YH; Ivars M; Moreno-Artero E; Trauner D; DeRoos ST; Jancic J; Nikolic M; Balážová P; Price HN; Hadzsiev K; Riney K; Stapleton S; Tollefson MM; Bauer D; Pinková B; Atkinson H
Br J Dermatol; 2023 Oct; 189(5):520-530. PubMed ID: 37463422
[TBL] [Abstract][Full Text] [Related]
28. Topical everolimus for facial angiofibromas in the tuberous sclerosis complex. A first case report.
Dill PE; De Bernardis G; Weber P; Lösch U
Pediatr Neurol; 2014 Jul; 51(1):109-13. PubMed ID: 24810875
[TBL] [Abstract][Full Text] [Related]
29. A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex.
Wheless JW; Almoazen H
J Child Neurol; 2013 Jul; 28(7):933-6. PubMed ID: 23680945
[TBL] [Abstract][Full Text] [Related]
30. Topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis: a systematic review based on evidence.
Cortell Fuster C; Martínez Gómez MA; Cercós Lleti AC; Climente Martí M
J Dermatolog Treat; 2022 Jun; 33(4):1804-1810. PubMed ID: 33821748
[TBL] [Abstract][Full Text] [Related]
31. [Topical sirolimus 0.4% formulation for treatment of facial angiofibromas].
Cuevas Asencio I; Albornoz López R; Salido Vallejo R; Reyes Malia M
Farm Hosp; 2012; 36(5):433-4. PubMed ID: 22858090
[No Abstract] [Full Text] [Related]
32. Targeted topical and combination laser surgery for the treatment of angiofibromas.
Bae-Harboe YS; Geronemus RG
Lasers Surg Med; 2013 Nov; 45(9):555-7. PubMed ID: 24136238
[TBL] [Abstract][Full Text] [Related]
33. Early Sirolimus Gel Treatment May Diminish Angiofibromas and Prevent Angiofibroma Recurrence in Children With Tuberous Sclerosis Complex.
Okanishi T; Fujimoto A; Enoki H; Ogai M
Front Med (Lausanne); 2020; 7():1. PubMed ID: 32039222
[No Abstract] [Full Text] [Related]
34. [Topical rapamycin solution to treat multiple facial angiofibromas in a patient with tuberous sclerosis].
Valerón-Almazán P; Vitiello M; Abuchar A; Kerdel FA
Actas Dermosifiliogr; 2012 Mar; 103(2):165-6. PubMed ID: 21861956
[No Abstract] [Full Text] [Related]
35. Topical 0.2% rapamycin to treat facial angiofibromas and hypomelanotic macules in tuberous sclerosis.
Knöpfel N; Martín-Santiago A; Bauza A; Hervás JA
Actas Dermosifiliogr; 2014 Oct; 105(8):802-3. PubMed ID: 24355193
[No Abstract] [Full Text] [Related]
36. Treatment of facial angiofibromas with topical application of oral rapamycin solution (1mgmL(-1) ) in two patients with tuberous sclerosis.
Mutizwa MM; Berk DR; Anadkat MJ
Br J Dermatol; 2011 Oct; 165(4):922-3. PubMed ID: 21692776
[No Abstract] [Full Text] [Related]
37. Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol.
DeKlotz CM; Ogram AE; Singh S; Dronavalli S; MacGregor JL
Arch Dermatol; 2011 Sep; 147(9):1116-7. PubMed ID: 21931059
[No Abstract] [Full Text] [Related]
38. Efficacy and Safety of Topical Mechanistic Target of Rapamycin Inhibitors for Facial Angiofibromas in Patients with Tuberous Sclerosis Complex: A Systematic Review and Network Meta-Analysis.
Lin YT; Yu CL; Tu YK; Chi CC
Biomedicines; 2022 Mar; 10(4):. PubMed ID: 35453576
[TBL] [Abstract][Full Text] [Related]
39. [Successful treatment of facial angiofibromas with local sirolimus in childhood in Bourneville-Pringle disease].
Bottyán K; Kemény L; Csoma ZR
Orv Hetil; 2019 Mar; 160(13):516-520. PubMed ID: 30907099
[TBL] [Abstract][Full Text] [Related]
40. Photodynamic therapy in a patient with facial angiofibromas due to tuberous sclerosis complex.
Shi M; He S; Chen P; Li Q; Zhu M; Guo J; Jiang L; Wang Q; Peng X; Li S; Li C; Zeng K
Photodiagnosis Photodyn Ther; 2019 Dec; 28():183-185. PubMed ID: 31398516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]